MediWound (MDWD) Stock Forecast & Price Target

MediWound is a promising company with a strong pipeline and revenue stream, including their FDA-approved product NexoBrid for severe burns. Their upcoming EscharEx trial for chronic wounds has potential for positive results, and the opportunity to expand into other indications could drive further growth in the future. A recent financial update showed lower than expected revenues, but management has reaffirmed their guidance and has a strong BARDA contract in place for future procurement.

MediWound is facing challenges with gaining favorable reimbursement in EU countries for its flagship product, NexoBrid, leading to poor revenue and a lack of profitability. This has resulted in a reduction of the price target by $2 to $30 with a more conservative view on future revenues, projecting only $21M for FY26. As a result, the outlook for MediWound's stock is negative, as the company's financial performance is not meeting expectations and there are significant challenges in its main market.